Pyrotinib
Advanced Gastroesophageal Junction Cancer
BeOne MedicinesSmall moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Advanced Gastroesophageal Junction Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab BeOne Medicines | Phase 1/2 | B |
Cetuximab BeOne Medicines | Phase 1 | CC |
Bgb-53038 BeOne Medicines | Phase 1 | CC |
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →